Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Cited by (1,034)

Items 101–200 of 1,034

1. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
   J. Huo, H. Mikolajek, A. Le Bas, J. Clark, Parul Sharma, A. Kipar, Joshua Dormon, Chelsea S. Norman, M. Weckener, D. Clare et al. · 2021 · Nature Communications
2. Antiviral neutralizing antibodies: from in vitro to in vivo activity
   Dennis R. Burton · 2023 · Nature reviews. Immunology
3. Age‐dependent and gender‐dependent antibody responses against <scp>SARS‐CoV</scp>‐2 in health workers and octogenarians after vaccination with the <scp>BNT162b2 mRNA</scp> vaccine
   Terpos, Evangelos, Trougakos, Ioannis P., Apostolakou, Filia, Charitaki, Ioanna, Sklirou, Aimilia D., Mavrianou, Nefeli, Papanagnou, Eleni‐Dimitra, Liacos, Christine‐Ivy, Gumeni, Sentiljana, Rentziou, Gianna et al. · 2021 · American Journal of Hematology
4. Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses
   J. Tas, Ja-Hyun Koo, Ying-Cing Lin, Zhenfei Xie, J. Steichen, A. Jackson, B. Hauser, Xuesong Wang, C. Cottrell, J. Torres et al. · 2022 · Immunity
5. Unsupervised evolution of protein and antibody complexes with a structure-informed language model
   Varun R. Shanker, Theodora U. J. Bruun, Brian Hie, Peter S. Kim · 2024 · Science
6. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
   P. Koenig, H. Das, Hejun Liu, B. Kümmerer, Florian N. Gohr, Lea-Marie Jenster, Lisa D. J. Schiffelers, Y. Tesfamariam, Miki Uchima, J. D. Wuerth et al. · 2021 · Science
7. Development of a rapid Focus Reduction Neutralization Test Assay for measuring SARS-CoV-2 neutralizing antibodies
   Abigail Vanderheiden, V. Edara, K. Floyd, Robert C Kauffman, G. Mantus, E. Anderson, N. Rouphael, S. Edupuganti, Pei-Yong Shi, V. Menachery et al. · 2020 · Current Protocols in Immunology
8. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
   Sabari Nath Neerukonda, Russell A. Vassell, Rachel Herrup, Shufeng Liu, Tony T. Wang, Kazuyo Takeda, Ye Yang, Tsai-Lien Lin, Wei Wang, Carol D. Weiss · 2021 · PLoS ONE
9. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
   C. Chakraborty, A. R. Sharma, M. Bhattacharya, G. Agoramoorthy, Sang-Soo Lee · 2021 · Frontiers in Pharmacology
10. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
    Harry Kleanthous, Judith M. Silverman, Karen W. Makar, In-Kyu Yoon, Nicholas M. Jackson, David W. Vaughn · 2021 · npj Vaccines
11. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
    Sham Nambulli, Yufei Xiang, N. L. Tilston-Lunel, L. Rennick, Z. Sang, W. Klimstra, D. Reed, N. Crossland, Yi Shi, W. P. Duprex · 2021 · Science Advances
12. Deep geometric representations for modeling effects of mutations on protein-protein binding affinity
    Liu, Xianggen, Luo, Yunan, Li, Pengyong, Song, Sen, Peng, Jian · 2021 · PLOS Computational Biology
13. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
    P. Pymm, Amy Adair, L. Chan, James P. Cooney, F. Mordant, C. Allison, E. Lopez, E. Haycroft, O, M. Neill et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
14. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
    T. Moyo-Gwete, Mashudu Madzivhandila, Z. Makhado, F. Ayres, D. Mhlanga, B. Oosthuysen, B. Lambson, P. Kgagudi, Houriiyah Tegally, A. Iranzadeh et al. · 2021 · bioRxiv
15. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
    Yunjiao Zhou, Zezhong Liu, S N Li, Wei Xu, Qianqian Zhang, Israel Tojal da Silva, Cheng Li, Yanling Wu, Qingling Jiang, Zhenmi Liu et al. · 2021 · Cell Reports
16. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
    Saya Moriyama, Yu Adachi, Takashi Sato, Keisuke Tonouchi, Lin Sun, Shuetsu Fukushi, Souichi Yamada, Hitomi Kinoshita, Kiyoko Nojima, Takayuki Kanno et al. · 2021 · Immunity
17. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
    Pan-Pan Zhou, Ge Song, Hejun Liu, Meng Yuan, Wanting He, Nathan Beutler, Xueyong Zhu, Longping V. Tse, David R. Martinez, Alexandra Schäfer et al. · 2023 · Immunity
18. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
    Pan-Pan Zhou, M. Yuan, G. Song, N. Beutler, N. Shaabani, De-Li Huang, Wan-ting He, Xue-Yong Zhu, Sean Callaghan, Peter Yong et al. · 2022 · Science Translational Medicine
19. Antibody-mediated neutralization of SARS-CoV-2
    Henning Gruell, Kanika Vanshylla, Timm Weber, Christopher O. Barnes, Christoph Kreer, Florian Klein · 2022 · Immunity
20. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
    C. Graham, J. Seow, I. Huettner, Hataf Khan, N. Kouphou, S. Acors, H. Winstone, S. Pickering, R. P. Galão, L. Dupont et al. · 2021 · Immunity
21. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
    Qi Zhang, Bin Ju, Jiwan Ge, Jasper Fuk‐Woo Chan, Lin Cheng, Ruoke Wang, Weijin Huang, Mengqi Fang, Peng Chen, Bing Zhou et al. · 2021 · Nature Communications
22. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2
    K. Vanshylla, V. Di Cristanziano, Franziska Kleipass, Felix Dewald, P. Schommers, L. Gieselmann, H. Gruell, M. Schlotz, M. Ercanoglu, Ricarda Stumpf et al. · 2021 · bioRxiv
23. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
    M. Joyce, Hannah A. D. King, Ines Elakhal-Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, C. Subra, Rita E. Chen, P. Thomas, Wei-Hung Chen et al. · 2021 · Science Translational Medicine
24. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
    Madeleine F. Jennewein, Anna J. MacCamy, Nicholas R. Akins, Junli Feng, Leah J. Homad, Nicholas K. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, Andrew B. Stuart, Venkata Viswanadh Edara et al. · 2021 · Cell Reports
25. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
    Zijun Wang, Frauke Muecksch, Alice Cho, Christian Gaebler, Hans-Heinrich Hoffmann, Víctor Ramos, Shuai Zong, Melissa Cipolla, Briana Johnson, Fabian Schmidt et al. · 2022 · Immunity
26. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
    Natalie Yan‐Lin Pang, Alexander Shao‐Rong Pang, Vincent T. K. Chow, De Yun Wang · 2021 · Military Medical Research
27. Antibody and B cell responses to SARS-CoV-2 infection and vaccination
    Katharina Röltgen, Scott Dexter Boyd · 2021 · Cell Host & Microbe
28. Neutralizing antibodies targeting SARS-CoV-2 spike protein
    Xiao-Jie Shi, Li Yu, Yan Lei, Yang Guang, Qiang Min · 2020 · Stem Cell Research
29. Neutralizing antibodies for the prevention and treatment of COVID-19
    Lanying Du, Yang Yang, Xiujuan Zhang · 2021 · Cellular and Molecular Immunology
30. SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
    Annachiara Rosa, V. E. Pye, C. Graham, L. Muir, J. Seow, K. Ng, N. Cook, C. Rees-Spear, Eleanor Parker, M. S. dos Santos et al. · 2021 · SciAdv
31. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
    Line K. Vibholm, S. Nielsen, M. H. Pahus, Giacomo S. Frattari, R. Olesen, R. Andersen, Ida Monrad, A. Andersen, Michelle M. Thomsen, C. Konrad et al. · 2021 · EBioMedicine
32. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
    Gregory Milne, Thomas Hames, Chris J. Scotton, Nick Gent, Alexander Johnsen, Roy Malcolm Anderson, Tom Ward · 2021 · The Lancet Respiratory Medicine
33. Neutralizing Antibody Therapeutics for COVID-19
    A. Hurt, A. Wheatley · 2021 · Viruses
34. Approaches and Challenges in SARS-CoV-2 Vaccine Development
    Dagotto, Gabriel, Yu, Jingyou, Barouch, Dan H. · 2020 · Cell Host &amp; Microbe
35. A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination
    Karen Colwill, Yannick Galipeau, Matthew Stuible, Christian Gervais, Corey R. Arnold, Bhavisha Rathod, Kento T. Abe, Jenny H. Wang, Adrian Pasculescu, Mariam Maltseva et al. · 2022 · Clinical & Translational Immunology
36. Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity
    R. Dolscheid-Pommerich, E. Bartok, Marcel Renn, B. Kümmerer, Bianca Schulte, R. Schmithausen, B. Stoffel-Wagner, Hendrik Streeck, S. Saschenbrecker, K. Steinhagen et al. · 2021 · Journal of Medical Virology
37. Protein N-myristoylation: functions and mechanisms in control of innate immunity
    Bin Wang, Tong Dai, Wen-Huan Sun, Yujun Wei, Jiang Ren, Long Zhang, Meng-Di Zhang, Fang-Fang Zhou · 2021 · Cellular & Molecular Immunology
38. SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants
    F. Tea, A. Stella, A. Aggarwal, D. Darley, Deepti Pilli, D. Vitale, V. Merheb, Fiona X. Z. Lee, P. Cunningham, G. Walker et al. · 2020 · medRxiv
39. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
    Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Shitu Mekonnen, Abtie Abebaw, Melese Getachew, Tengchuan Jin · 2021 · Seminars in Immunology
40. Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
    Chen, Xinhua, Chen, Zhiyuan, Azman, Andrew S, Sun, Ruijia, Lu, Wanying, Zheng, Nan, Zhou, Jiaxin, Wu, Qianhui, Deng, Xiaowei, Zhao, Zeyao et al. · 2022 · Clinical Infectious Diseases
41. Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates
    Shuyu Shou, Menghui Liu, Yang Yang, Ning Kang, Yingying Song, Dan Tan, Nan-Nan Liu, Feifei Wang, Jing Liu, You-Hua Xie · 2021 · Frontiers in Microbiology
42. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
    S. Madhi, A. Koen, A. Izu, L. Fairlie, C. Cutland, V. Baillie, S. Padayachee, K. Dheda, S. Barnabas, Q. Bhorat et al. · 2021 · The Lancet HIV
43. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
    Ryutaro Kotaki, Yu Adachi, Saya Moriyama, Taishi Onodera, Shuetsu Fukushi, Takaki Nagakura, Keisuke Tonouchi, Kazutaka Terahara, Lin Sun, Tomohiro Takano et al. · 2022 · Science Immunology
44. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
    Joyce K. Hwang, Tian Zhang, Andrew Zhuang Wang, Zihai Li · 2021 · Journal of Hematology & Oncology
45. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
    Hyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, Meng Yuan, Mary Peterson, Janie Y. Liang, Nathan Beutler, Jonathan L. Torres, Yu Cong, Elena N. Postnikova et al. · 2021 · Science Translational Medicine
46. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
    Yuan-Ling Yu, Meiyu Wang, Xiao-Ai Zhang, Shu-Fen Li, Qing-yue Lu, Hao-Long Zeng, Hongyan Hou, Hao Li, Meng-Yi Zhang, F. Jiang et al. · 2021 · Signal Transduction and Targeted Therapy
47. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
    Benjamin Trinité, Ferran Tarrés-Freixas, Jordi Rodon, Edwards Pradenas, Víctor Urrea, Sílvia Marfil, Maria Luisa Rodrı́guez de la Concepción, Carlos Ávila‐Nieto, Carmen Aguilar‐Gurrieri, Ana Barajas et al. · 2021 · Scientific Reports
48. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
    Savannah E. Butler, Andrew R. Crowley, Harini Natarajan, Shiwei Xu, Joshua A. Weiner, Carly A. Bobak, Daniel E. Mattox, Jiwon Lee, Wendy Wieland‐Alter, Ruth I. Connor et al. · 2021 · Frontiers in Immunology
49. Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer’s Disease, Parkinson’s Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome
    T. Satoh, D. Trudler, Chang-ki Oh, S. Lipton · 2022 · Antioxidants
50. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
    Vivek Naranbhai, Wilfredo F. García-Beltrán, Christina C. Chang, Cristhian Berrios, Julia Thierauf, Grace Kirkpatrick, Maristela Lika Onozato, Ju Cheng, Kerri St. Denis, Evan Christopher Lam et al. · 2021 · The Journal of Infectious Diseases
51. Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection
    Susanna K. Elledge, Xin X. Zhou, James R. Byrnes, Alexander J. Martinko, Irene Lui, Katarina Pance, Shi-On A. Lim, J. Glasgow, A. Glasgow, K. Turcios et al. · 2021 · Nature Biotechnology
52. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
    Xi-Lin Wu, Lin Cheng, Ming Fu, Bilian Huang, Lin-Jing Zhu, Shijie Xu, Haixia Shi, Dou-Dou Zhang, Huanyun Yuan, Waqas Nawaz et al. · 2021 · bioRxiv
53. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
    Liu, Zhuoming, VanBlargan, Laura A., Bloyet, Louis-Marie, Rothlauf, Paul W., Chen, Rita E., Stumpf, Spencer, Zhao, Haiyan, Errico, John M., Theel, Elitza S., Liebeskind, Mariel J. et al. · 2020
54. An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity
    Francesco Borriello, Valentina Poli, Ellen L. Shrock, Roberto Spreafico, Xin Liu, Novalia Pishesha, Claire Carpenet, Janet S. Chou, Marco Di Gioia, Marisa E. McGrath et al. · 2022 · Cell
55. Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection
    Chengzi I. Kaku, Alan J. Bergeron, Clas Ahlm, Johan Normark, Mrunal Sakharkar, Mattias N.E. Forsell, Laura M. Walker · 2022 · Science Immunology
56. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry
    Julián Valero, Laia Civit, Daniel M. Dupont, Denis Selnihhin, Line Sinnathamby Reinert, Manja Idorn, Brett A. Israels, Aleksandra Bednarz, Claus Bus, Benedikt Asbach et al. · 2021 · Proceedings of the National Academy of Sciences
57. Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD
    E. J. Carr, A. Kronbichler, M. Graham-Brown, Graham Abra, C. Argyropoulos, L. Harper, E. Lerma, Rita S. Suri, J. Topf, M. Willicombe et al. · 2021 · Kidney International Reports
58. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
    Song, Ge, He, Wan-ting, Callaghan, Sean, Anzanello, Fabio, Huang, Deli, Ricketts, James, Torres, Jonathan L., Beutler, Nathan, Peng, Linghang, Vargas, Sirena et al. · 2020
59. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice
    Chih-Jen Wei, Wei Bu, L. Nguyen, J. Batchelor, JungHyun Kim, S. Pittaluga, J. Fuller, Hanh Nguyen, Te-Hui Chou, Jeffrey I. Cohen et al. · 2022 · Science Translational Medicine
60. The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients
    Huanle Luo, Tingting Jia, Jiamin Chen, Shike Zeng, Zengzhao Qiu, Shu Wu, Xu Li, Yuxuan Lei, Xin Wang, Weihua Wu et al. · 2021 · Frontiers in Immunology
61. Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants
    Natália Teruel, Olivier Mailhot, Rafaël Najmanovich · 2021 · PLoS Computational Biology
62. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
    Dufloo, Jérémy, Grzelak, Ludivine, Staropoli, Isabelle, Madec, Yoann, Tondeur, Laura, Anna, François, Pelleau, Stéphane, Wiedemann, Aurélie, Planchais, Cyril, Buchrieser, Julian et al. · 2021 · Cell Reports Medicine
63. SARS-CoV-2 Spreads through Cell-to-Cell Transmission
    Cong Zeng, John P. Evans, T. King, Yi-Min Zheng, Eugene M. Oltz, Sean P. J. Whelan, L. Saif, M. Peeples, Shan-Lu Liu · 2021 · bioRxiv
64. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID‐19 Therapy
    Feng Xie, Peng Su, Ting Pan, Xiaoxue Zhou, Heyu Li, Hui-Zhe Huang, Ai-Jun Wang, Fang-Wei Wang, Jun Huang, Hai-Yan Yan et al. · 2021 · Advances in Materials
65. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
    Laura A. VanBlargan, L. Adams, Zhuo-Ming Liu, Rita E. Chen, P. Gilchuk, S. Raju, Brittany K. Smith, Hai-Yan Zhao, J. Case, Emma S. Winkler et al. · 2021 · Immunity
66. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies
    Dongyan Zhou, J. Chan, Biao Zhou, Run-Hong Zhou, Shuang Li, S. Shan, Li Liu, A. Zhang, Serena J. Chen, C. Chan et al. · 2021 · Cell Host and Microbe
67. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
    M. Dogan, L. Kozhaya, L. Placek, Courtney Gunter, Mesut Yi̇ği̇t, R. Hardy, Matthew Plassmeyer, Paige Coatney, Kimberleigh Lillard, Z. Bukhari et al. · 2021 · Communications Biology
68. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
    A. Deshpande, Bethany D. Harris, L. Martínez-Sobrido, J. Kobie, M. Walter · 2021 · bioRxiv
69. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
    Emelissa J. Valcourt, Kathy Manguiat, Alyssia Robinson, Chih‐Yu Chen, Kristina Dimitrova, Clark S. Phillipson, Lise Lamoureux, Elizabeth McLachlan, Zachary Schiffman, MICHAEL A. DREBOT et al. · 2020 · Diagnostic Microbiology and Infectious Disease
70. Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
    den Hartog, Gerco, Vos, Eric R A, van den Hoogen, Lotus L, van Boven, Michiel, Schepp, Rutger M, Smits, Gaby, van Vliet, Jeffrey, Woudstra, Linde, Wijmenga-Monsuur, Alienke J, van Hagen, Cheyenne C E et al. · 2021 · Clinical Infectious Diseases
71. The Importance and Challenges of Identifying SARS-CoV-2 Reinfections
    A. Babiker, C. Marvil, J. Waggoner, M. Collins, A. Piantadosi · 2020 · Journal of Clinical Microbiology
72. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant
    Thorne, Lucy G, Bouhaddou, Mehdi, Reuschl, Ann-Kathrin, Zuliani-Alvarez, Lorena, Polacco, Ben, Pelin, Adrian, Batra, Jyoti, Whelan, Matthew V.X., Ummadi, Manisha, Rojc, Ajda et al. · 2021
73. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
    Tingting Li, Hongmin Cai, Hebang Yao, Bingjie Zhou, Ning Zhang, Martje Fentener van Vlissingen, Thijs Kuiken, Wenyu Han, Corine H. GeurtsvanKessel, Yuhuan Gong et al. · 2021 · Nature Communications
74. Neutralizing antibodies for the treatment of COVID-19
    Shi-Bo Jiang, Xiujuan Zhang, Yang Yang, P. Hotez, L. Du · 2020 · Nature Biomedical Engineering
75. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
    F. Chiuppesi, M. Salazar, Heidi Contreras, V. Nguyen, Joybelle Martinez, Yoonsuh Park, Jenny Nguyen, Mindy Kha, A. Iniguez, Qiao Zhou et al. · 2020 · Nature Communications
76. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
    Pan-Pan Zhou, M. Yuan, G. Song, N. Beutler, N. Shaabani, De-Li Huang, Wan-ting He, Xue-Yong Zhu, Sean Callaghan, Peter Yong et al. · 2021 · bioRxiv
77. Distant residues modulate conformational opening in SARS-CoV-2 spike protein
    Dhiman Ray, L. Le, I. Andricioaei · 2020 · Proceedings of the National Academy of Sciences of the United States of America
78. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
    Anton M. Sholukh, Andrew J. Fiore-Gartland, Emily S. Ford, Maurine D. Miner, Yixuan Jacob Hou, Longping V. Tse, Hannah Kaiser, Haiying Zhu, Joyce Lu, Bhanupriya Madarampalli et al. · 2021 · Journal of Clinical Microbiology
79. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Yu Guo, Lisu Huang, Guangshun Zhang, Yanfeng Yao, He Zhou, Shū Shěn, Bingqing Shen, Bo Li, Xin Li, Qian Zhang et al. · 2021 · Nature Communications
80. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection
    H. Yao, Yao Sun, Yong-Qiang Deng, Nan Wang, Yongcong Tan, Na-Na Zhang, Xiao-Feng Li, Chao Kong, Yan-Peng Xu, Qi Chen et al. · 2020 · Cell Research
81. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
    Pei Tong, Avneesh Kumar Gautam, Ian W. Windsor, Meghan E. Travers, Yuezhou Chen, Nicholas Garcia, Noah B. Whiteman, Lindsay G. A. McKay, Nadia Storm, Lauren E. Malsick et al. · 2021 · Cell
82. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
    Nicholas K. Hurlburt, Leah J. Homad, Irika R. Sinha, Madeleine F. Jennewein, Anna J. MacCamy, Yu-Hsin Wan, Jim B. Boonyaratanakornkit, Anton M. Sholukh, Abigail M. Jackson, Pan-Pan Zhou et al. · 2022 · Communications Biology
83. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
    Katherine Nabel Smith, Sarah A. Clark, Sundaresh Shankar, Junhua Pan, Lars E. Clark, Pan Yang, Adrian Coscia, Lindsay G. A. McKay, Haley Varnum, Vesna Brusic et al. · 2022 · Science
84. Decay of Fc-dependent antibody functions after mild to moderate COVID-19
    Wen Shi Lee, Kevin John Selva, Samantha K. Davis, Bruce D. Wines, Arnold Reynaldi, Robyn Esterbauer, Hannah G. Kelly, Ebene R. Haycroft, Hyon‐Xhi Tan, Jennifer A. Juno et al. · 2021 · Cell Reports Medicine
85. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies
    Xun Chen, Matteo Gentili, N. Hacohen, A. Regev · 2021 · Nature Communications
86. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
    Dennis Lapuente, Thomas Winkler, Matthias Tenbusch · 2023 · Cellular and Molecular Immunology
87. Development and deployment of COVID-19 vaccines for those most vulnerable
    Wayne Chester Koff, Theodore Schenkelberg, Tere M. Williams, Ralph Steven Baric, Adrian B. McDermott, Cheryl Cameron, Mark J. Cameron, Matthew B. Frieman, Gabriele Neumann, Yoshihiro Kawaoka et al. · 2021 · Science Translational Medicine
88. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
    Vivek Naranbhai, Claire A. Pernat, Alexander Gavralidis, Kerri St. Denis, Evan Christopher Lam, Laura M. Spring, Steven Jay Isakoff, Jocelyn R. Farmer, Leyre Zubiri, Gabriela S. Hobbs et al. · 2021 · Journal of Clinical Oncology
89. Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster
    Lun-Zhi Yuan, Hua-Chen Zhu, Ming Zhou, Jian Ma, Rirong Chen, Yao Chen, Liqiang Chen, Kun Wu, M. Cai, Junping Hong et al. · 2021 · Signal Transduction and Targeted Therapy
90. Tackling COVID-19 with neutralizing monoclonal antibodies
    Corti, Davide, Purcell, Lisa A., Snell, Gyorgy, Veesler, David · 2021 · Cell
91. SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
    E. Scherer, A. Babiker, M. Adelman, B. Allman, A. Key, J. Kleinhenz, Rose M. Langsjoen, Phuong-Vi Nguyen, I. Onyechi, J. D. Sherman et al. · 2022 · New England Journal of Medicine
92. Technology and Entrepreneurial Marketing Decisions During COVID-19
    M. R. H. Polas, Valliappan Raju · 2021 · Global Journal of Flexible Systems Management
93. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection
    Xiao-Lin Jiang, Guo-Lin Wang, Xiang-Na Zhao, Fei-Hu Yan, Lin Yao, Z. Kou, Shengxiang Ji, Xiao-li Zhang, Cunbao Li, L. Duan et al. · 2021 · Nature Communications
94. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
    Carlos A Cruz-Teran, Karthik Tiruthani, Morgan D. McSweeney, Alice D. Ma, R. Pickles, S. Lai · 2020 · Advanced Drug Delivery Reviews
95. Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain
    2021
96. Hydrogel‐Based Slow Release of a Receptor‐Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS‐CoV‐2
    Emily C. Gale, Abigail E. Powell, Gillie A. Roth, Emily L. Meany, Jerry Yan, Ben S. Ou, Abigail K. Grosskopf, J. Adamska, Vittoria C. T. M. Picece, Andrea I. d'Aquino et al. · 2021 · Advances in Materials
97. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
    Elaine C. Chen, P. Gilchuk, Seth J. Zost, Naveenchandra Suryadevara, Emma S. Winkler, C. R. Cabel, E. Binshtein, Rita E. Chen, Rachel E. Sutton, Jessica L. Rodriguez et al. · 2021 · Cell Reports
98. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
    Daniel E. Asarnow, Bei Wang, Wen-Hsin Sandy Lee, Yuanyu Hu, Ching-Wen Huang, Bryan Faust, Patricia Miang Lon Ng, Eve Zi Xian Ngoh, Markus‐Frederik Bohn, David P. Bulkley et al. · 2021 · Cell
99. Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
    Chengzi I. Kaku, Elizabeth R. Champney, Johan Normark, Marina García, Carl E. Johnson, Clas Ahlm, Wanda Christ, Mrunal Sakharkar, Margaret E. Ackerman, Jonas Klingström et al. · 2022 · Science
100. Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies
     Zach Troyer, Najwa Alhusaini, Caroline O. Tabler, Thomas J. Sweet, Karina Inacio Carvalho, Daniela Schlatzer, Lenore L. Carias, Christopher L. King, Kenneth A. Matreyek, John C. Tilton · 2021 · Journal of Extracellular Vesicles